The production of scientific posters and poster books for the pharmaceutical industry is a job for the experts, demanding a combination of the highest levels of professionalism and technical expertise. The Cinnamon Agency understands this, and has had a wealth of experience working with some of the industry’s major pharmaceutical brands at conferences, events and symposia throughout the world.
The Cinnamon Agency, working in conjunction with Adelphi Communications, recently produced 3 scientific posters for our client Roche Pharmaceuticals for The British Society for Rheumatology conference and Symposium on rheumatoid arthritis and other auto-immune diseases on 12/14 April, 2011 at the Hilton Metropole Hotel in Brighton. Roche Pharmaceuticals, based in Welwyn Garden City, is one of the world’s leading producers of autoimmune disease therapies, like MabThera and Rituxan, and works in conjunction with clinicians, healthcare professionals and patients to offer new hope to sufferers, by developing biopharmaceutical products that pave the way for new treatments that can impede the progression of autoimmune diseases and prevent joint damage and pain.
Our Brief
Our brief was to produce 3 scientific posters for our client, Roche Pharmaceuticals, to draw attention and focus to the new, innovative research work they were doing in the autoimmune disease field. At the BSR Conference, experts discussed the proposed changes in the NHS environment and its impact on rheumatology. Rheumatoid arthritis is one of the most common autoimmune diseases and affects 21 million people worldwide. In 30 to 40% of cases, conventional drug treatments are both ineffective and poorly tolerated.
Researchers at Roche Pharmaceuticals are looking at innovative ways to deepen their understanding of the immune system and pinpoint the causes and course of arthritis. Their discoveries have already resulted in new drugs offering real patient benefits. Biopharmaceuticals such as MabThera / Rituxan in rheumatoid arthritis selectively intervene in the molecular course of the disease without weakening the immune system as a whole. This new mechanism of action alleviates pain and holds the disease in check.
Currently doctors rely on a constellation of signs and symptoms to make a firm diagnosis of rheumatoid arthritis. By that time, many patients are already disabled by their damaged joints. Roche Pharmaceutical’s goal is earlier detection, using a reliable disease indicator in the form of a biomarker, incorporated in a diagnostic test. Only then will doctors be able to intervene early enough to prevent joint damage and disability.